Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (331-340 of 525) with videos related to

Pageof 53
Sort By:
Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2012
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agentsLaura A McAllister, Justin I Montgomery, Joseph A Abramite, et al.
The Journal of Clinical Investigation|October 1, 2019
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialNadine G Rouphael, Cecilia Morgan, Shuying S Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Eclinicalmedicine|May 9, 2020
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in <i>Mycobacterium tuberculosis</i>-uninfected adolescents in Cape Town, South AfricaLinda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Journal of Virology|January 7, 2014
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaquesM Anthony Moody, Sampa Santra, Nathan A Vandergrift, et al.
Frontiers in Immunology|August 8, 2022
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 StudyBeatriz Perdiguero, Benedikt Asbach, Carmen E Gómez, et al.
Pageof 53

Showing results (331-340 of 525) with videos related to

Sort By:
Pageof 53
Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2012
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agentsLaura A McAllister, Justin I Montgomery, Joseph A Abramite, et al.
The Journal of Clinical Investigation|October 1, 2019
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialNadine G Rouphael, Cecilia Morgan, Shuying S Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Eclinicalmedicine|May 9, 2020
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in <i>Mycobacterium tuberculosis</i>-uninfected adolescents in Cape Town, South AfricaLinda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Journal of Virology|January 7, 2014
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaquesM Anthony Moody, Sampa Santra, Nathan A Vandergrift, et al.
Frontiers in Immunology|August 8, 2022
Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 StudyBeatriz Perdiguero, Benedikt Asbach, Carmen E Gómez, et al.
Pageof 53